The availability of these new mAbs will greatly improve cost-effective investigation on the prevalence of Stx1-producing STEC in food, the environment, and in clinical samples, and offer a potential treatment of HUS. The gene discussed is STX1A; the disease is hemolytic-uremic syndrome.